Stockscreener 앱 받기
8.53
0.00%
0.00
시간 외 거래:
8.53
전일 마감가:
$8.53
열려 있는:
$8.53
하루 거래량:
573.84K
Relative Volume:
0.81
시가총액:
$387.59M
수익:
$84.82M
순이익/손실:
$-21.43M
주가수익비율:
-17.41
EPS:
-0.49
순현금흐름:
$-27.23M
1주 성능:
+0.12%
1개월 성능:
+93.42%
6개월 성능:
+49.13%
1년 성능:
-35.96%
1일 변동 폭
$8.53
$8.54
1주일 범위
$8.5113
$8.54
52주 변동 폭
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
명칭
Y Mabs Therapeutics Inc
전화
646-885-8505
주소
202 CARNEGIE CENTER, PRINCETON, NY
YMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
8.53 | 387.14M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-11-18 | 개시 | Oppenheimer | Outperform |
| 2024-08-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-28 | 개시 | Truist | Buy |
| 2023-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-04-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-12-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-10-31 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-10-31 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재개 | Guggenheim | Buy |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-11-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-23 | 재개 | Cowen | Outperform |
| 2021-03-22 | 재개 | JP Morgan | Overweight |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-05-01 | 개시 | Janney | Buy |
| 2020-04-29 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-12-24 | 개시 | JP Morgan | Overweight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 개시 | Wedbush | Outperform |
| 2019-04-01 | 개시 | H.C. Wainwright | Buy |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-10-16 | 개시 | BofA/Merrill | Buy |
모두보기
Y Mabs Therapeutics Inc 주식(YMAB)의 최신 뉴스
Halper Sadeh Investigates Veritex, TaskUs, Y-mAbs Merger Activity - AInvest
Ranking Y mAbs Therapeutics Inc. among high performing stocks via toolsEarnings Risk Summary & Short-Term Trading Alerts - Newser
How to interpret RSI for Y mAbs Therapeutics Inc. stockMarket Growth Review & Safe Swing Trade Setups - Newser
Is this a good reentry point in Y mAbs Therapeutics Inc.Quarterly Earnings Summary & Stepwise Trade Execution Plans - Newser
Can volume confirm reversal in Y mAbs Therapeutics Inc.2025 Price Momentum & Verified Swing Trading Watchlists - Newser
Will Y mAbs Therapeutics Inc. outperform the marketTrade Exit Summary & Verified Entry Point Signals - Newser
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY - GlobeNewswire
Will Y mAbs Therapeutics Inc. continue its uptrendJuly 2025 Spike Watch & Daily Oversold Bounce Ideas - Newser
Long term hold vs stop loss in Y mAbs Therapeutics Inc.Fed Meeting & Growth Focused Stock Pick Reports - Newser
Can trapped investors hope for a rebound in Y mAbs Therapeutics Inc.July 2025 WrapUp & Risk Adjusted Swing Trade Ideas - Newser
Custom strategy builders for tracking Y mAbs Therapeutics Inc.Market Sentiment Review & Free Technical Pattern Based Buy Signals - Newser
Y-mAbs Therapeutics (NASDAQ:YMAB) and Viridian Therapeutics (NASDAQ:VRDN) Financial Survey - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNOW, TASK, YMAB on Behalf of Shareholders - The Malaysian Reserve
Measuring Y mAbs Therapeutics Inc.’s beta against major indicesIndex Update & AI Driven Price Forecasts - Newser
Is Y mAbs Therapeutics Inc. stock risky to hold now2025 Price Targets & Growth-Oriented Investment Plans - thegnnews.com
Signal strength of Y mAbs Therapeutics Inc. stock in tech scannersJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - Newser
Can Y mAbs Therapeutics Inc. scale operations efficientlyWeekly Trade Review & Expert Curated Trade Ideas - thegnnews.com
What institutional flow reveals about Y mAbs Therapeutics Inc.July 2025 PostEarnings & Community Consensus Trade Alerts - Newser
Intraday pattern recognizer results for Y mAbs Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - Newser
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock - MSN
Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease - insights.citeline.com
Y-mAbs Therapeutics’ SWOT analysis: acquisition shakes up oncology stock outlook - Investing.com Nigeria
Y-mAbs soars on take-private deal with SERB Pharmaceutical - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, DNOW on Behalf of Shareholders - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. (NYSEWOW), BankFinancial Corporation (NasdaqBFIN), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nas - Morningstar
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Brookline Capital Management - MarketBeat
How Efficient Is Y mAbs Therapeutics Inc. at Controlling Operating CostsShort Term Opportunity Finder with Tools - Newser
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial - MarketBeat
Analyzing Y mAbs Therapeutics Inc. with risk reward ratio chartsOversold Reversal Picks with Buy Zone - Newser
DeFi Technologies Provides Monthly Corporate Update: Valour Reports US$947 Million (C$1.3 Billion) in AUM, and Monthly Net Inflows of US$14.4 Million (C$19.8 Million) in July 2025, Among Other Key Developments - The Globe and Mail
Y-mAbs Therapeutics (NASDAQ:YMAB) Given Hold Rating at Jones Trading - MarketBeat
11 Best Short-Term Stocks to Invest in - Insider Monkey
Chart based analysis of Y mAbs Therapeutics Inc. trendsYearly Trend Summary and Opportunity Breakdown - Newser
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Neutral" Rating from HC Wainwright - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) - Eastern Progress
SERB Pharmaceuticals Acquires Y-MAbs As Revenue Slides - Finimize
Y-mAbs Therapeutics 2025 Q2 Earnings Narrowed Losses and Pending Acquisition - AInvest
HC Wainwright Downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) to Hold - Defense World
Y-mAbs Therapeutics Reports Q2 Earnings and Acquisition - TipRanks
Y-mAbs (YMAB) Q2 Revenue Falls 14% - AOL.com
Y Mabs Therapeutics Inc (YMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Y Mabs Therapeutics Inc 주식 (YMAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rossi Michael J | PRESIDENT & CEO |
Mar 07 '25 |
Sale |
5.20 |
3,917 |
20,368 |
137,083 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
0.94%
1.72%
자본화:
|
볼륨(24시간):